Saved in:
Bibliographic Details
Main Authors: Fu, Youlin, Zhang, Peng, Chen, Feng, Xie, Ziqiang, Xiao, Shihui, Huang, Zhihao, Lau, Cia-Hin, Zhu, Haibao, Luo, Jun
Format: Artículo científico
Language:en
Published: Molecular biology reports 2025
Subjects:
Online Access:https://pubmed.ncbi.nlm.nih.gov/39797940/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1868266258125815809
author Fu, Youlin
Zhang, Peng
Chen, Feng
Xie, Ziqiang
Xiao, Shihui
Huang, Zhihao
Lau, Cia-Hin
Zhu, Haibao
Luo, Jun
author_facet Fu, Youlin
Zhang, Peng
Chen, Feng
Xie, Ziqiang
Xiao, Shihui
Huang, Zhihao
Lau, Cia-Hin
Zhu, Haibao
Luo, Jun
Fu, Youlin
Zhang, Peng
Chen, Feng
Xie, Ziqiang
Xiao, Shihui
Huang, Zhihao
Lau, Cia-Hin
Zhu, Haibao
Luo, Jun
collection PubMed - marine biology
contents CRISPR detection of cardiac tumor-associated microRNAs. Fu, Youlin Zhang, Peng Chen, Feng Xie, Ziqiang Xiao, Shihui Huang, Zhihao Lau, Cia-Hin Zhu, Haibao Luo, Jun Humans MicroRNAs Heart Neoplasms CRISPR-Cas Systems Myxoma Hemangiosarcoma Biomarkers, Tumor As multiple imaging modalities cannot reliably diagnose cardiac tumors, the molecular approach offers alternative ways to detect rare ones. One such molecular approach is CRISPR-based diagnostics (CRISPR-Dx). CRISPR-Dx enables visual readout, portable diagnostics, and rapid and multiplex detection of nucleic acids such as microRNA (miRNA). Dysregulation of miRNA expressions has been associated with cardiac tumors such as atrial myxoma and angiosarcoma. Diverse CRISPR-Dx systems have been developed to detect miRNA in recent years. These CRISPR-Dx systems are generally classified into four classes, depending on the Cas proteins used (Cas9, Cas12, Cas13, or Cas12f). CRISPR/Cas systems are integrated with various isothermal amplifications to detect low-abundance miRNAs. Amplification-free CRISPR-Dx systems have also been recently developed to detect miRNA directly. Herein, we critically discuss the advances, pitfalls, and future perspectives for these CRISPR-Dx systems in detecting miRNA, focusing on the diagnosis and prognosis of cardiac tumors.
format Artículo científico
id pubmed_39797940
institution PubMed
language en
publishDate 2025
publisher Molecular biology reports
record_format pubmed
spellingShingle CRISPR detection of cardiac tumor-associated microRNAs.
Fu, Youlin
Zhang, Peng
Chen, Feng
Xie, Ziqiang
Xiao, Shihui
Huang, Zhihao
Lau, Cia-Hin
Zhu, Haibao
Luo, Jun
Humans
MicroRNAs
Heart Neoplasms
CRISPR-Cas Systems
Myxoma
Hemangiosarcoma
Biomarkers, Tumor
CRISPR detection of cardiac tumor-associated microRNAs. Fu, Youlin Zhang, Peng Chen, Feng Xie, Ziqiang Xiao, Shihui Huang, Zhihao Lau, Cia-Hin Zhu, Haibao Luo, Jun Humans MicroRNAs Heart Neoplasms CRISPR-Cas Systems Myxoma Hemangiosarcoma Biomarkers, Tumor As multiple imaging modalities cannot reliably diagnose cardiac tumors, the molecular approach offers alternative ways to detect rare ones. One such molecular approach is CRISPR-based diagnostics (CRISPR-Dx). CRISPR-Dx enables visual readout, portable diagnostics, and rapid and multiplex detection of nucleic acids such as microRNA (miRNA). Dysregulation of miRNA expressions has been associated with cardiac tumors such as atrial myxoma and angiosarcoma. Diverse CRISPR-Dx systems have been developed to detect miRNA in recent years. These CRISPR-Dx systems are generally classified into four classes, depending on the Cas proteins used (Cas9, Cas12, Cas13, or Cas12f). CRISPR/Cas systems are integrated with various isothermal amplifications to detect low-abundance miRNAs. Amplification-free CRISPR-Dx systems have also been recently developed to detect miRNA directly. Herein, we critically discuss the advances, pitfalls, and future perspectives for these CRISPR-Dx systems in detecting miRNA, focusing on the diagnosis and prognosis of cardiac tumors.
title CRISPR detection of cardiac tumor-associated microRNAs.
topic Humans
MicroRNAs
Heart Neoplasms
CRISPR-Cas Systems
Myxoma
Hemangiosarcoma
Biomarkers, Tumor
url https://pubmed.ncbi.nlm.nih.gov/39797940/